The price of the EpiPen has risen more than 400 percent over the last eight years and a Connecticut member of Congress is calling on the manufacturer to lower prices and for a federal investigation into pricing.
The life-saving device that holds an emergency dose of epinephrine is critical for treating people with life-threatening allergic reactions and the price has jumped from $56.64 to $317.82, according to an NBC News report.
Families need to buy EpiPens every year because they expire and need to be replaced.
U.S. Senator Richard Blumenthal has reached out to the manufacturer, Mylan, and is also calling for the Senate Judiciary Committee and the Federal Trade Commission to investigate what he calls potential anti-trust violations and deceptive and illegal trade practices.
“My office has been contacted by dozens of concerned Connecticut residents, families, school nurses, and first responders who urgently require your life-saving product but fear that its skyrocketing price has put it out of reach. Due to Mylan’s virtual monopoly of the epinephrine auto-injector market and its unique life-saving attribute, it is crucial that your product remains affordable. Therefore, I demand that Mylan take immediate action to lower the price of EpiPens for all who rely on this product for their health and safety,” Blumenthal wrote in a letter to Mylan.